• TDS Moderators: AlphaMethylPhenyl | Eligiu | deficiT

Mental Health New wave of research puts psychedelics forward to treat mental health ->

hallucinations-drug-abuse_f_600x250.jpg



Australian approval of psychedelic therapy expected within five years

by Lisa Martin | 11 Jul 2019

Psychedelic therapy involving magic mushrooms or MDMA to treat mental illnesses could be five years away from regulator approval in Australia and the Victorian government is being urged to make the state a research leader in the field.

The US Food and Drug Administration recently designated the treatment as “breakthrough therapies” following successful medical trials. International trials are finding synthetic magic mushroom therapy is effective in treating depression, anxiety and addiction while MDMA therapy is helping post-traumatic stress disorder sufferers. The treatment could receive US regulatory approval as early as 2021. The UK, Canada, Europe and Israel are also active research hubs.

In a submission to Victoria’s mental health royal commission, Mind Medicine Australia – which lobbies for psychedelic-assisted treatments for mental health – urges the state government to chip in funding to establish a centre for excellence in psychedelic medicine. It would conduct research and develop best practice and training for therapists.

Mind Medicine Australia executive officer Dr Paul Liknaitzky said the stigma around the therapy has been lifting globally in the past 15 years and there was an opportunity to play catch up.

“Australia has been pretty slow in the uptake,” he told Guardian Australia.

In an Australian-first, St Vincent’s hospital in Melbourne announced in January a psychedelic medicine trial will start this year. It is recruiting 30 palliative care patients to be treated with synthetic magic mushrooms aimed to ease the paralysing anxiety often associated with having a terminal illness. The trial is expected to start in six to eight weeks.

“We urgently need to explore new treatment paradigms and the promise of psychedelic medicines in terms of alleviation of suffering cannot be under-estimated,” St Vincent psychiatrist David Castle said.

Liknaitzky emphasised the treatment was more than just about pills and going on a trip – there was also an important element of talk therapy involved.

“The particular way participants are prepared and supported matters a lot,” he said.

Liknaitzky noted overseas follow-up studies had found 80% of participants using magic mushroom therapy to treat smoking addiction had successfully quit and the use of MDMA therapy for PTSD had a 70% success rate.

PTSD will affect one in 13 Australians in their lifetimes.

Liknaitzky said psychedelic therapy had the potential to save the health system a lot of money in the long term compared to conventional treatments. He said between one to three sessions can be effective.

He estimated the therapy could be approved in Australia in about five years.

There was a flurry of research into psychedelic therapy treatments in the 1950s and 1960s but then US president Richard Nixon launched a crackdown in 1971, classifying all psychedelics as prohibited substances. This was in the context of concern over growing recreational use of hallucinogenic drugs and the youth anti-Vietnam war protest movement.

“We owe it to every person suffering with mental illness and their families to not be held hostage by historical prejudices and to identify the best solutions available to alleviate the increasing suffering in our community,” Liknaitzky said.

American retired US army sergeant Jonathan Lubecky, who suffered crippling PTSD, has penned a letter about his experience with psychedelic therapy to the Victorian royal commission.

Lubecky was deployed to the Iraq war in 2005 and was on a military base that was mortared thousands of times. Within 60 days of returning to the US, he made five suicide attempts.

“The effect this treatment has had on my life has been nothing short of a miracle,” he wrote. “My suicidal ideation slowed and then stopped. My depression also improved greatly over time. I now lead a full and rich life.”

The Royal Australian and New Zealand College of Psychiatrists president, John Allan, is cautious about psychedelic therapy.

“They are quite potent drugs and they have a history of causing quite a lot of trouble when they have been used recreationally in the past,” Allan told the Guardian. “There’s a very low evidence base. It’s still experimental and the exact treatment protocols have not been decided. It’s early days.”

Allan said the royal commission should not recommend that public funding be spent on psychedelic therapy research because there were more important spending priorities in mental health. “This is a luxury item,” he said.

 
Last edited:
dat-consciousness-neurosciennwes.jpg



Psychedelics: Paradigm shift in mental health care?*

by Erin Allday | San Francisco Chronicle | June 1, 2019

UCSF psychiatrist Brian Anderson is studying an experimental therapy to help long-term AIDS survivors — people who were infected with HIV in the 1980s and never expected to live this long — who are feeling sad and demoralized.

In a clinic outfitted with a comfortable couch, soft lighting, throw pillows and blankets, the participants of his study are given psilocybin, the hallucinogenic compound found in magic mushrooms. They lie down for a few hours, a mask over their eyes and soothing music playing in the background, and experience a psychedelic trip.

The next day, they talk to Anderson or one of his colleagues about the trip. Then they start group therapy to talk about issues around survival: long-held grief over the loss of friends or partners, deeply rooted stigma of being gay and HIV-positive, their fear of dying. For several of the 18 men in Anderson’s initial study, it was their first time talking about these hard issues.

“We know from other trials that people seem to talk more openly about very challenging emotional material during the drug experience and after the drug treatment,” Anderson said. “Our participants told us they started to really process some events from the distant past or face things that they’ve been avoiding."

“Was it because they went through the drug experience? We don’t know,”
he added. But the results were compelling enough that he’s planning a second study with female long-term survivors.

Anderson’s work is part of a resurgence in psychedelic study that has been brewing over the past decade — and that is now, at least to some degree, fueling grassroots efforts around the country to decriminalize use of certain psychedelic drugs.

Oakland recently decriminalized psychedelic plants, making the East Bay city the second in the United States to pass such policy; the first was Denver last month. Statewide measures are being discussed in California and Oregon.

The decriminalization efforts are focused on natural psychedelics — mushrooms, along with herbs, cacti and other plants from which hallucinogenic compounds can be extracted. Whether the movements will expand to include synthetic psychedelics such as LSD and MDMA, or eventually lead to efforts to legalize the drugs, remains to be seen.

The activity — both in politics and in medicine — represents a sort of national psychedelic revival. Though several studies in the first half of the 20th century had shown promise in using psychedelics for treatment of mental health and neurological disorders, the drugs were broadly maligned in the 1960s and ’70s, largely because of public concern over recreational use of LSD.

Anti-drug campaigns that leaned on horror stories of bad trips and tales of healthy people turned psychotic led to the outlawing of LSD in 1966. Later, all psychedelics were placed under the government’s Schedule 1 category of drugs, officially designating them as having no therapeutic use. Almost all formal study of psychedelics ended.

An underground community of psychedelic providers and users remained, and actually thrived in places like the Bay Area, where counterculture activities have always found support. MDMA was popular through the 1990s and 2000s in the Bay Area’s club and rave scene. More recently, microdosing — the practice taking small, carefully controlled amounts of a psychedelic — has taken off among Silicon Valley techies and university students who believe it boosts productivity and creativity.

All over the region are informal networks of people who will provide psychedelics to those who are dealing with intractable mental health issues, for whom approved pharmaceutical drugs and mainstream therapy has fallen short. People grow hallucinogenic plants in community gardens or their backyards, and they create safe spaces in their homes for others who want to use the drugs.

But in the academic community, the resumption of medical research really only started a few years ago. Now a new generation of scientists is picking up where their predecessors left off.

“I came across the older era of psychedelic research in the late ’90s, when I was in college. I recognized it as a fascinating scientific history for which these threads were left dangling,” said Matthew Johnson, an associate professor in psychiatry and behavioral sciences at Johns Hopkins University who has studied using psychedelics to change behavior.

LSD is still largely ignored in medical research. But scientists across several fields, mostly in mental health, are taking renewed interest in the potential of other psychedelic drugs to treat everything from addiction and social anxiety to chronic depression and post-traumatic stress.

Most of the research has been focused on two synthetic drugs: MDMA and a lab-made version of psilocybin that mimics the compound found in hallucinogenic mushrooms. Some scientists are asking that psilocybin be taken off the Schedule 1 list, which would ease access to federal research funds and potentially make it easier to get approval for medical applications. Almost all studies at the moment rely on private donations for funding.

Even if studies prove that psychedelics are useful for treating certain conditions, it would probably be years before they win federal approval and — legally — reach consumers. The closest to getting there seems to be MDMA, specifically as a treatment for post-traumatic stress syndrome.

Two years ago, the Food and Drug Administration designated MDMA a “breakthrough therapy” for PTSD, which could speed the approval process. Early clinical trials have found that the drug is effective for two-thirds of study participants. Phase 3 studies — the final stretch before seeking approval — have started, with plans to enroll at least 200 participants. Researchers have asked that the FDA allow compassionate use for patients who suffer extreme symptoms of PTSD and for whom no other treatments have worked.

“We’re talking about a paradigm shift with mental health care,” said Ismail Lourido Ali, policy and advisory counsel for MAPS, which is running the PTSD trial. “Our results are about twice as effective as the next closest available treatment. We’re in the process of studying MDMA therapy for social anxiety in adults with autism, and MDMA for eating disorders."

“The momentum is great, but at the same time, we’re not talking about silver bullets here,”
he added.

Studies are still limited, but they’re happening at universities around the country. There’s Anderson’s long-term survivors trial at UCSF. At Johns Hopkins, Johnson and his colleagues reported about an 80% success rate in using psilocybin to help people quit smoking in one small study. Research out of UCLA has found that psilocybin may help cancer patients with depression and anxiety.

"But it’s far too soon to suggest that psychedelics are going to be a panacea for a bundle of mental health and neurological conditions," said Keith Humphreys, an addiction specialist at Stanford.

Psychedelics aren’t addictive, he said, but they carry other risks, including the potential for a small subset of people to suffer chronic psychosis after using them. Some users can have psychedelic trips that are terrifying or cause them to hurt themselves or others.

Mostly, though, Humphreys said he’s not convinced that the drugs will end up being all that useful. Most of the evidence so far is from trials with just a handful of participants, or from observational or anecdotal reports.

“It’s very common in psychiatry to have a small clinical trial, and everyone is so desperate for a new treatment and this looks like the answer — and then we do bigger and better designed studies and the bloom comes off the rose,” Humphreys said. “It has nothing to do with the history of psychedelics or that these drugs come from plants. I could list a dozen medications we’ve seen it with. It’s hype.”

"How psychedelics may help people with mental health issues isn’t clear. People who have had a psychedelic trip often say they were able to evaluate parts of their lives — past trauma, relationships with others, ongoing existential crises — from a detached point of view while on the drugs. That gave them new perspective or allowed them to place certain problems in a new context."

“People often report examining parts of their past memories or strong emotions in ways that they weren’t able to without help of the drug,”
Anderson said of the participants in his long-term survivors study. “They create a new meaning about what happened to them.”

Andre Humphrey, 38, said psychedelics helped him confront years of abuse from his childhood that left him so traumatized that it affected his ability to go to school, keep a job, maintain positive relationships and even stay physically safe and healthy.

He was so moved by his psychedelic experiences that he eventually quit a job in real estate and decided to open a clinic in Oakland to help children from at-risk communities who have experienced trauma access yoga, meditation and other “metaphysical healing” therapies — though not psychedelics. He’s calling his operation Inner City Bliss.

The most profound of his psychedelic trips came when he consumed ayahuasca, a South American beverage made from several plant-based ingredients. While he was under the influence, a child came to him that he recognized as himself.

“I told him that I forgave him. It was life-changing,” Humphrey said. “It made me realize that I needed to love myself more, be easier on the little child. It made me realize that inner child is real and I need to handle him differently. I need to love him.

“After the ayahuasca,”
he said, “I cried for like two hours.”

*From the article here :
 
Last edited:
5912aa4d1600002000c5a613.png



Podcast : Are psychedelics the new wonder drug for mental illness?

Dr. Mark Hyman | Apr 19 2019

The reputation of psychedelics as recreational and dangerous has hindered investigation of their therapeutic potential. Now, we are seeing increased interest of drugs like this, which include compounds like psilocybin from certain species of mushrooms, for therapeutic uses. Trials are finding amazing effects on anxiety, depression, PTSD, and fear of death by using psychedelics in a responsible and highly controlled environment.

If you missed this week’s episode of The Doctor’s Farmacy, my guest Dr. Anthony Bossis discusses the value in researching medicinal psychedelics. Anthony is a clinical psychologist and clinical assistant professor of psychiatry at NYU School of Medicine investigating the effects of psilocybin. Dr. Bossis was the director of palliative care research, co-principal investigator, co-author, and session guide on the 2016 landmark study showing a significant reduction in emotional distress along with enhanced existential wellbeing from a single psilocybin-generated mystical experience in persons with cancer.

Throughout our talk, Dr. Bossis sheds light on the untapped resource of psychedelic therapy when it comes to mental illness and end of life care. Many people with fatal diagnoses have overcome their fear of death and made amends with unfinished business in his trials. His professional experiences, profound scientific knowledge, and complex insights make it clear that there is more to this story than you might have thought.

We also dive into the topic of overcoming trauma and reframing mindset. Dr. Bossis talks about how psychedelic therapy can allow us to see ourselves within a much larger landscape, a process that recalibrates our sense of self and who or what we may be connected to.

This is a truly unique and fascinating episode. I hope you’ll take this opportunity to learn more about a topic that we’ll be hearing a lot more about in the years to come.

 
Last edited:
HealingWorld2-1000x642.jpg



How psychedelic substances help treat anxiety, depression and other mental illnesses

by Jeremy Hobson and Serena McMahon | Oct 09 2019

The world of psychedelic research is expanding.

Johns Hopkins University has launched a center for psychedelic research with $17 million in donations solely from private donors, the first of its kind in the U.S.

The establishment of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine signals “a new era of research in therapeutics and the mind,” according to the center’s director, Roland Griffiths.

That comes on the heels of the U.S. Food and Drug Administration’s announcement earlier this year that it had approved esketamine, a substance chemically-related to the party drug ketamine, as a nasal spray to treat depression.

The potential of psychedelics for treating mental illnesses — such as anxiety, depression, addiction, PTSD and more — has been the primary research interest of psychologist William Richards for more than 50 years, though for more than two decades he couldn’t engage in the field.

Richards began his journey with psychedelics in the early ‘60s, in the midst of a wave of psychedelic research, when he was a graduate student in Germany and volunteered for a psilocybin trial.

“That was before I had even heard the word ‘psychedelic,’” he says. “I had this incredibly profound experience. And in many ways, the rest of my life is footnotes to that experience.”

But by the late ‘60s, popular opinion on the substances had soured, and the federal government deemed psychedelics — such as LSD and psilocybin — Schedule 1 drugs. American universities slowed their research, and the field ground to a halt in 1977, when Richards administered the last dose of psilocybin to a patient for more than two decades.

The Schedule 1 classification, which is still in use for psychedelics today, means the government considers them “drugs with no currently accepted medical use and a high potential for abuse.”

“I would say that arose out of the cultural change in fears back in the 1960s,”
Richards says. “It's distorted. It’s inaccurate.”

In 1999, he began working with other researchers at Johns Hopkins to kick the field into gear again, eventually publishing a paper on “mystical-type experiences” with psychedelics in 2006.

Psychedelics show “immense” promise when it comes to treating mental health disorders, he says. The university’s new center may usher in “a whole new era” of treatment for the millions of Americans affected by mental illness each year.

Despite a few caveats, such as if a person has an acute heart condition or genetic predisposition for severe mental illness, he says, the substances are “remarkably safe” for most people.

“They're not toxic. They're not addictive,” he says. “And they can be profoundly helpful.”

When psychedelic substances such as psilocybin or LSD are managed properly and responsibility, Richards says the patients often only need to be administered the drug one or two times to experience its “healing” properties.

"It’s the memory of the drug that’s healing," he says.

“You remember that something shifted in your view of yourself, your view of other people, your view of the world, your understanding of what it is to be a human being,” he says. “And that's incredibly fascinating and powerful.”

During a trial with Richards and his team, a patient first establishes a “solid, trust-filled relationship” with a therapist or guide over a week or longer. Then, once the patient is comfortable, the psilocybin is administered in a “safe and caring” atmosphere — similar to a living room.

That supportive environment allows patients to “feel free to just kind of sink into their minds, embrace whatever emerges — whether it’s pleasant or unpleasant initially — and trust the healing processes of their own minds,” he says.

Richards remains fascinated by the way many people, while on psychedelic substances, seem to be able to tap into the wisdom within their own minds.

“The human mind knows how to heal itself if you give it the trust-filled atmosphere and the opportunities to become deeply aware of the levels of consciousness within you,” he says.

"Proper preparation, the correct dose and a safe environment are all helpful to reduce the chances of becoming frightened," he says, "because the drug can be disorienting."

He says some patients on psychedelic substances might find themselves working through grief, guilt or confusion.

“But it can be profoundly therapeutic in a very rapid space of time,” he says.

He hopes furthering research at Johns Hopkins University will lead to legal, insurance-covered psilocybin therapy, specifically in palliative care, which would assist those nearing death in coping with anxiety and depression.

“In the work we've done with terminally ill people, those who have mystical experiences often claim loss of the fear of death,” he says.

The fear of death is displaced by curiosity spurred in the mind after using a psychedelic, he explains, which may allow them to live “much more fully” during the final period of their lives.

But his mission isn’t just to research. "It’s also to educate against the misconceptions, inaccurate information and ignorance that have invaded the psychiatric world for years," he says.

He and his team are grasping onto this moment in time where the interest in psychedelics is swelling in the U.S. and parts of Europe, which he says is thanks to the dedication of both young and mid-career scientists enthusiastic about the field.

Decades into the “footnote” of his first psilocybin experience, Richards is watching the field he loves make an astounding comeback.

“I hope to stick around to see it flourish,” he says, “but I have no doubt that it will continue to expand whether I'm here or not.”

 
Last edited:
rendered.jpg

Cannabidiol reduces the brain activity linked to hallucinations, delusions
and other forms of psychosis, research has found.


Brain scans show how CBD may help people with psychosis

CBD reduces the brain activity linked to hallucinations, delusions and other forms of psychosis, research has found.

Brain scans have revealed for the first time how a substance found in cannabis plants may help people with psychotic disorders by dampening down abnormal brain activity that arises in the patients.

A single dose of CBD, an non-intoxicating extract of the plant, reduced unusual patterns of neural behaviour linked to hallucinations, delusions, and other symptoms of psychosis, researchers found.

The impact of the substance has raised hopes that medical preparations of pure CBD, or new drugs based on the compound, may be turned into effective treatments for young people who develop psychosis but do not respond to existing therapies.

The most common treatments for psychosis today work on a brain chemical called dopamine, but no new drugs have been developed for the condition since they were discovered in the 1950s. “These results will clearly pave the way for developing a novel class of antipsychotic treatments,” said Sagnik Bhattacharyya, who led the research at King’s College London.

Cannabis plants produce more than 100 active compounds known as cannabinoids. The most potent, and the substance responsible for the cannabis “high”, is THC. In the past two decades, cannabis with high levels of THC – about 15% – has come to dominate the market in the UK and elsewhere.

While high strength cannabis is suspected of raising the risk of mental health problems in some frequent cannabis users, cannabidiol or CBD appears to have opposite, antipsychotic properties. In cannabis, there is too little CBD to have much beneficial effect, but researchers have long wondered whether doses of pure CBD may help to protect against psychosis.

“We knew from previous studies that CBD had antipsychotic effects, but we didn’t know how it worked,” said Bhattacharyya.

To find out, the researchers recruited 33 people who had all sought help for mild or occasional psychotic symptoms, such as hearing voices or having paranoid delusions. A single dose of cannabidiol was given to 16 of them, while the remaining 17 received an identical-looking placebo.

The scientists then watched how the volunteers’ brains behaved as they performed simple tasks in a magnetic resonance imaging machine. While in the brain scanner, the participants were asked to say whether pairs of words, such as ‘baby’ and ‘cries’ were related or not, and later, to recall the word that completed a pair when prompted by the scientists.

When the researchers compared scans from the different patient groups, and with scans from age and sex-matched healthy people, they found that the patients with psychotic symptoms had abnormal patterns of activity in three distinct brain regions, all of which are involved in psychosis. But in patients who had a single dose of CBD, the unusual brain activity appeared to be dampened down, making their scans more similar to those of health individuals. Details of the work are published in JAMA Psychiatry.

“This was just a single dose of CBD and that is not going to treat or cure psychosis,” said Bhattacharyya. “But this shows us that CBD at least has an effect on abnormal brain activity that is consistent with it being an antipsychotic.”

The King’s College researchers are now launching the first large scale trial to investigate whether pure, medical grade CBD is an effective treatment for young people who are at high risk of developing psychosis. The trial, which is expected to start recruiting early next year, is backed by the Medical Research Council and the National Institute for Health Research.

“If the trial shows it has efficacy, then the next step will be to get through the regulatory hurdles os using CBD in the clinic to treat patients,” said Bhattacharyya. “One shouldn’t get the impression that it’s OK to start prescribing CBD tomorrow.”

https://www.theguardian.com/science...nnabis-extract-may-help-people-with-psychosis
 
Last edited:
2e6b2e40be5ebd8724c79eb44bd1d328.jpg



Could psychedelics help to heal the crisis of disconnection?

by Sam Gandy, Rosalind Watts & Alex Evans

We urgently need tools that can facilitate connection and foster a common sense of purpose for protecting and restoring our world.

Disconnection, in a broad sense, may be the root of a number of our civilisation’s major ills.

Unless this disconnection - to self, self with others, and the natural world - is addressed, the future of our species on this planet is likely in jeopardy.

It's widely considered that we have entered the sixth mass extinction of life on this planet, due entirely to human actions on the biosphere. The publication of the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) report in May of this year makes for grim reading. Complied by 145 expert authors from 50 countries assessing changes over the past 50 years, the assessment found that nature is declining at rates unprecedented in human history, with ecological degradation and rates of species extinctions accelerating, with over a million species now threatened with extinction.

This has dire implications for the biosphere at large, as well as the survival of our species, with fundamental, transformative change from local to global scales now essential to reverse this dire trend.

Interestingly, the only areas not undergoing ecological degradation were those inhabited and managed by indigenous people, and in fact such areas may even harbour greater biodiversity than protected areas. One common thread linking indigenous groups all over the world is that they tend to be very strongly connected to nature and highly protective of their surrounding environment.

When this connection to nature is very high, people often view their surrounding environment as an extension of themselves, which increases the desire to protect it. We have lost this connection as a side effect of our materialistic, technological civilisation, and the ecologically protective intuition that stems from it. Indigenous groups also tend to have a much stronger community connectedness, with more of a group centered existence, living less individualistic, egoic lives than us in the Western world. This stands in contrast to the idea of the ‘separate self’ which has become central to Western societies over the past five centuries, from the Enlightenment’s emphasis on rigid lines between mind and matter, or humans and nature, all the way through to contemporary trends such as consumerism, falling social capital and status anxiety.

Our disconnection from nature seems to have begun once we transitioned from hunter gatherers to farmers, which fundamentally changed the way our species perceived and interacted with the natural world. The existence of certain species and groups of people were valued over the existence of others, and nature was a resource to be tamed and controlled. Our domestication of plant and animal species was two way, and this process sowed the seeds of the civilisation we know today. For the first time we started in living in larger and increasingly urban population centres, which has acted to disconnect us from nature further. The most recent wake of nature disconnection seems to be being fuelled by our increasing technological dependency, with our growing screen addictions rendering us prisoners of the paradox that the more we watch, the less we see of the world around us.

If a growing disconnection from nature is fuelling the ecological crisis, a growing interpersonal disconnection and disconnection from core self is fuelling the mental health crisis. A sense of disconnection is linked to poor mental health, including depression, with a sense of connection or connectedness being linked to psychological well-being, and recovery of mental health. One small but noteworthy study exploring the effectiveness of psilocybin therapy for the treatment of major depression found that 85% responded to varying degrees, and an enhanced sense of connectedness was commonly reported by those whose symptoms improved, with depression frequently tied to feelings of disconnection. Feelings of disconnection have also been associated with use of SSRI antidepressants, which are commonly prescribed for depression sufferers. In another study, it was found that 94% of these people reported a new sense of connection to the world around them, with an increased connection to others noted up to a year later. Interestingly, a deeper ‘connection to self' was also frequently reported. This does not imply a connection to ‘ego self’, but rather a sense of expanded connection linked to people’s ‘true self’, tied to one’s emotions and intuition, and guided by an inner sense of meaning, purpose, empathy and compassion.

f21aae42648a930b6b53bd094b186f8c.jpg


In the qualitative follow-up, participants offered these reports:

“Like Google Earth, I had zoomed out … I was absolutely connected to myself, to every living thing, to the Universe.”

“This connection, it’s just a lovely feeling…this sense of connectedness, we are all interconnected."


Research has already shown that experience with psychedelics strongly predicts an increased connection to, or self-identification with nature, with self-reported engagement with pro-environmental behaviours stemming from this. Albert Hofmann, the scientist who first synthesised LSD in 1938, came to view the capacity of psychedelics to reconnect humans with nature as perhaps their most important and fundamental property. Shortly before his death, at the mighty age of 101, he said that:

“Alienation from nature and the loss of the experience of being part of the living creation is the greatest tragedy of our materialistic era. It is the causative reason for ecological devastation and climate change. Therefore I attribute absolute highest importance to consciousness change. I regard psychedelics as catalysers for this.”

Psychedelics can unlock a newfound appreciation of nature, a profound sense of being part of a much larger whole and of a magnificent interconnected web of life – something that has been described again and again in experience reports, research surveys, experimental studies and historical accounts of early psychedelic experiences. In this respect, psychedelics can be considered as biophilia enhancing agents. Biophilia, a term coined by biologist E. O. Wilson, refers to our innate fondness for nature, or “the connections that human beings subconsciously seek with the rest of life.” Our species has spent 99.99% of its existence living in natural environments, for which our physiology and psychology is adapted. In a recent survey of 150 psychedelic users, all reported that biophilia was enhanced.

Psychedelics are not required to increase feelings of nature connection, the physical sensory experience of being in nature alone is sufficient to enhance it. However not everyone is fortunate enough to have grown up with access to nature, and without childhood contact with nature, a connection may be lacking. It seems that the power of psychedelics may be to increase nature connection in people who are highly disconnected from it, and so play a role in converting ‘nature sceptics'. An increased acknowledgement of nature has also been implicated in fostering connectedness in a broader sense, including to people, nature and life as a whole.

There is a significant body of research literature to show that high ratings of nature connection are strongly correlated with reduced levels of anxiety, greater happiness and positive affect, life meaning and vitality, and improved psychological well-being, and that degree of nature connection also mediates some of the benefits one gains from spending time in nature. Nature connection is also considered a strong predictor of pro-environmental behaviours, outperforming all other tested variables as a single construct. It seems that an emotional, empathic connection to nature is needed to motivate behavioural change, and that concern arises as a side effect of this deepening connection.

The breakdown of communities and the associated disconnection and loneliness that follows in its wake is considered a major health issue, worse than smoking and on par with obesity. Depression is on the rise, considered by the World Health Organisation as the leading cause of disability worldwide. It seems that, in part, rising depression and suicide rates are symptomatic of a sick society. Growing disconnection, and its associated individualism appears to also be playing out in the global political sphere, with increasing disconnection catalysing greater division, evidenced by a tendency toward tribalism and polarisation of global politics.

Global politics appear to be becoming increasingly ‘triggered’, with growing anxiety cultivating a widespread, polarising ‘us-and-them’ mentality. This in turn creates opportunities for political populists and authoritarian leaders to take power through wielding a combination of psychology, technology and communications. As a result of disconnection and the division that it fosters, leaders may be more inclined to gain votes by making promises to build physical walls between people rather than bridges. This growing political polarisation should be of grave concern, and has led many analysts to become increasingly concerned about the breakdown of common ground and capacity for societies to feel a shared sense of purpose and identity. This division prevents us from effectively responding to some of the toughest and most urgent challenges that humans must face, including global climatic change and accelerating ecological destruction. The only hope we have at solving issues on this scale is for societies to come together with a more cohesive and strongly shared sense of purpose.

Psychedelics can be considered agents of connection. At the level of the neuron, they increase synaptic and neurite connections. At the level of the brain, they increase global connectivity, facilitating communication between different brain regions. They facilitate increased connection of the self, and self with others, and they can enhance our connection to nature and the world at large. Their ability to enhance connectedness may be linked to their effects on the ego, or our sense of subjective self-identity. An overly ‘rigid’ ego may play a major role in both depression and nature disconnection, with egoic separateness walling us off in private prisons and disconnecting us from our core selves, other people and the world around us, narrowing our perspective. Under a high dose of a psychedelic such as psilocybin, a brain network called the default mode network, which is a fundamental component of the neural basis of the ego, is relaxed and deactivated. The deepened connection people describe may stem from the unitive states that are made accessible by this blurring of boundaries that ego dissolution facilitates. This appears to be the mechanism through which perceived boundaries between self and other dissolve, catalysing an expanded perspective of self-nature overlap. The deepened connection to nature people describe post psychedelic experience also appears to be an enduring perspective shift, lasting at least a year.

Contemporary scientific research is highlighting the capacity of psychedelics to facilitate connection between people, and the environment they are a part of. As humanity faces a deepening ecological crisis, we urgently need tools that can facilitate connection, foster empathy and a shared sense of common purpose for protecting and restoring our world, while allowing us to identify with a ‘larger us’…one that includes all the world’s people, other species and generations as yet unborn. This is similar to the view commonly ascribed to the profound cognitive shift known as the ‘overview effect’ described by astronauts viewing the Earth from space. It may be that psychedelics provide an alternative but more accessible and egalitarian route to a similar transformative vantage point. What if rather than vilifying these compounds, we held them in the same high regard as some indigenous groups do? How different might our global future look if that were the case?

One of the reasons for the success of our species is our ability to identify with and cooperate at ever-larger collectives and scales of complexity: from Neolithic tribes to chiefdoms, from city-states to kingdoms, from nation-states to global diasporas and, just 50 years ago, the first photograph of Earth snapped from space by NASA astronaut Bill Anders.

However, as we become a more global society, local communities are surrendering their identity and resources to the larger unit. A crisis of economic extraction is a factor here; 84 % of global ‘stock’ is now held by the wealthiest 10%. Bennet A Zellner’s work on ‘inclusive economic development’ describes how as in nature, healthy economic systems support an interdependent web, whereas unhealthy systems focus on extraction. He describes how a promising alternative model, the ‘pollinator’ approach, seeks to heal community systems by renewing and recirculating resources locally. In the future, psychedelic healthcare could adopt the pollinator model, with healthcare hubs like thriving beehives which nurture and rejuvenate the local ecosystem. Psychedelics offer promise as a treatment for depression, addiction, existential anxiety in those with a terminal illness diagnosis, and the evidence base is rapidly increasing. The psychedelic treatment centres of the future could be part of a new paradigm of community-based wellness. For this, we have much to learn from some indigenous groups.

At this moment, humanity appears poised between breakdown and breakthrough. A breakdown scenario would see us fragment into small groups as a primary consequence of our growing disconnection and political division, with potentially catastrophic results given the severity of the challenges we face at a global scale. Our only hope in facing these challenges would be through a breakthrough, which would see humanity jump to a much higher level of coherence and interconnection, and one essential if planetary level problems are to be addressed…much as evolution saw the emergence of novel complex systems, from cells to organs, and neurons to brains. The key variable that will tip the balance between these two scenarios is psychological, hinging on how we see ourselves and each other, whether we feel connected or threatened, and the size of the collective with which we identify. The solutions to the issues we face may reside in re-establishing our lost connection to the natural world, and each other, the ultimate source of our collective well-being.

 
Last edited:
rat-brain-empathy-neurosciencenews-public.jpg



Psychedelics can be used to help treat a variety of psychiatric disorders*

by Chris Moore | Sep 20 2019

A new scientific review published in this month's Journal of Psychiatric Practice reported that psychedelics have successfully been used to reduce symptoms linked to at least eight different psychiatric disorders. And since today is National Psilocybin Mushroom Day, we figured there was no better time to break down this news for you.

Researchers from the University of Texas Health Science Center at San Antonio reviewed sixteen previously-published studies exploring whether psychedelic drugs could help treat a variety of disorders. These original studies, published between 1946 and 2017, examined the effects of ibogaine, ketamine, LSD, MDMA, psilocybin, ayahuasca, and other drugs on patients suffering from conditions like depression, substance use disorders, and PTSD.

“The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders,” the researchers wrote. “The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated.”

Out of the 16 studies reviewed, 15 found that psychedelic-based therapy “produced clinically significant reduction in” symptoms of psychiatric disorders.

Specifically, the review noted two studies that found that ayahuasca helped reduce the symptoms of treatment resistant depression, and another study which found that MDMA-assisted therapy helped patients deal with PTSD associated with sexual trauma. Several other studies found that ibogaine, ketamine, LSD, and dipropyltryptamine (a synthetic psychedelic known as DPT or “The Light”) all showed evidence of helping patients struggling with substance use disorder remain sober.

The researchers explained that many of these studies were flawed, due to small subject size or lack of control groups, making it “difficult to draw definite conclusions” about the research. However, the study concluded that “this body of pilot literature suggests the possibility of therapeutic benefit that could outweigh adverse events and warrants more rigorous, definitive investigation.”

“Despite promising findings in therapeutic psychedelic trials, current factors, including funding, laws, and stigma, continue to impose limitations on further research,”
the review concluded. “Schedule I classification makes study development difficult, costly, and prolonged. Funding by both government and pharmaceutical companies is nonexistent.”

Despite the ongoing federal prohibition of these drugs, research into their therapeutic potential has been booming in recent years. Both MDMA and psilocybin have been granted “breakthrough therapy” status by the Food and Drug Administration (FDA), allowing researchers to conduct federally-approved research on these drugs. Based on the success of these trials, both of these psychedelics could gain federal approval to be used under medical supervision within years. Ketamine, once known as party drug “Special K,” has already been approved by the FDA to help treat serious depression.

The University of Texas review notes that around 40 million Americans, or 15.3 percent of the country's population, have used psychedelics, according to the 2015 National Survey on Drug Use and Health. That number may well be growing, as Denver and Oakland have both decriminalized psilocybin and other psychedelics, and other cities and states are working to do the same.

*From the article here :
 
Last edited:
800px-Shulgin_sasha_2011_hanna_jon.jpg



Inside the centre exploring the effects of psychedelic drugs on mental health

by Benedict Carey | The Independent | 23 Sep 2019

Since childhood, Rachael Petersen had lived with an unexplainable sense of grief that no drug or talk therapy could entirely ease. So in 2017 she volunteered for a small clinical trial at Johns Hopkins University that was testing psilocybin, the active ingredient in magic mushrooms, for chronic depression.

“I was so depressed,” Petersen, 29, recalls. “I felt that the world had abandoned me, that I’d lost the right to exist on this planet. Really, it was like my thoughts were so stuck, I felt isolated.”

The prospect of tripping for hours on a heavy dose of psychedelics was scary, she says, but the reality was profoundly different: “I experienced this kind of unity, of resonant love, the sense that I’m not alone anymore, that there was this thing holding me that was bigger than my grief. I felt welcomed back to the world.”

Earlier this month, Johns Hopkins Medicine introduced the Centre for Psychedelic and Consciousness Research, to study compounds like LSD and psilocybin for mental health problems, including anorexia, addiction and depression. The centre is the first of its kind in the country, established with $17m (£14m) in commitments from wealthy private donors and a foundation. Imperial College London created what is thought to be the world’s first such centre in April, with some $4m from private sources.

“This is an exciting initiative that brings new focus to efforts to learn about mind, brain and psychiatric disorders by studying the effects of psychedelic drugs,” Dr John Krystal, chair of psychiatry at Yale University, says about the Johns Hopkins centre.

The centres at Johns Hopkins and Imperial College give “psychedelic medicine”, as some call it, a long-sought foothold in the scientific establishment. Since the early 2000s, several scientists have been exploring the potential of psychedelics and other recreational drugs for psychiatric problems, and their early reports have been tantalizing enough to generate a stream of positive headlines and at least two popular books. The emergence of depression treatment with the anaesthetic and club drug ketamine and related compounds, which cause out-of-body sensations, also has piqued interest in mind-altering agents as aids to therapy.

But the drugs’ history of abuse and the still-thin evidence base have kept the field largely on the fringes, and many experts are still wary. Psychedelic trials cannot be “blinded” in the same way most drug trials are: participants know when they have been dosed, and reports of improvement are not yet standardised.

“It raises the caution that the investigation of hallucinogens as treatments may be endangered by grandiose descriptions of their effects and unquestioning acceptance of their value,” Dr Guy Goodwin, a professor of psychiatry at Oxford, wrote in a recent commentary in the Journal of Psychopharmacology.

Beach-Tripping-709x473.jpg


The scientists doing the work, at Hopkins, Imperial College and elsewhere, acknowledge as much and say the new funding will help clarify which drugs help which patients, and when the altered states are ineffectual or potentially dangerous.

“It’s been hand to mouth in this field, and now we have the core funding and infrastructure to really advance psychedelic science in a way that hasn’t been done before,” says Roland Griffiths, a neuroscientist at Johns Hopkins who will direct the new centre. Griffiths says the new funds would cover six full-time faculty members, five postdoctoral scientists and the costs of running trials. Among the first of those trials are a test of psilocybin for anorexia nervosa and of psilocybin for psychological distress and cognitive impairment in early Alzheimer’s disease.

“The one that’s crying out to be done is for opiate-use disorder, and we also plan to look at that,” Griffiths says.

Trials using psychedelics or other mind-altering drugs tend to have a similar structure. Participants, whether they have a diagnosis of PTSD, depression or substance abuse, do extensive preparation with a therapist, which includes a complete medical history and advice and information about the study drug. People with a history of psychosis are typically excluded, as psychedelics can exacerbate their condition. And those on psychiatric medications usually taper off beforehand.

On treatment day, the person comes into the clinic, takes the drug and sits or lies down, under continuous observation by a therapist, who provides support and occasional guidance as the drug’s effects become felt. In the Johns Hopkins trial that Petersen joined, participants wore eyeshades and headphones, lay down and listened to music.

“The first trip lasted 6½ hours, and I didn’t move,” she recalls. A week later, she returned for another dose; each dose was about twice what recreational users take. Therapy using psychedelics or other mind-altering compounds typically involves just one or two sessions on the drug.

“I would be lying if I said aspects of my experience weren’t deeply challenging and upsetting,” Petersen says. “The therapist would grab my hand – would save me in a moment – and encourage me to adopt a posture of welcoming everything, like a meditation.”

The literature so far, from trials like these, suggests that psilocybin is promising for chronic depression and addiction, and that MDMA, or ecstasy, can help people with post-traumatic stress. Cannabis and LSD also have been tried, for addiction and other problems, with mixed results.

One finding many drug studies share is that any positive effects are far more likely to last if the participant has an especially intense trip. The intensity is graded using a variety of measures, including what scientists call the MEQ, for “mystical experience, questionnaire,” although Griffiths allows that the term is misleading.

“That was a significant branding mistake because awe is not fun,” he says. “There’s something existentially shaking about these experiences.”

It is that existential reckoning, the theory goes, that prompts many people to rejigger their identities or priorities in a way that reduces habitual behaviours or lines of thinking that cause distress.

In a continuing trial, Matthew Johnson, an addiction specialist at Johns Hopkins and a member of the new psychedelic centre, is investigating how psilocybin treatment compares with use of a nicotine patch in helping people to quit smoking. So far, in the 39 people who have been in the study for at least six months, the abstinence rate in the psilocybin group is 50 per cent, compared with 32 per cent using the patch.

“The most compelling thing that makes psilocybin different from other addiction drugs is that it’s showing this cross-drug efficacy,” Johnson says. “It appears to have a similar effect, regardless of what drug the person is addicted to.”

That great potential, across many different diagnoses, is what attracted a small group of donors to Johns Hopkins, said Tim Ferriss, who brought in half the donated amount from investors, including more than $2m from himself. Ferriss, an investor and author, says that depression and addiction ran in his own family and that available treatments were often inadequate. His investment in the centre, he says, “was a chance to have a large output from a small input – a real Archimedes lever.” The Steven & Alexandra Cohen Foundation provided the balance of the commitments.

Petersen is convinced that her psilocybin trip made a lasting difference. She's had one relapse since the trial, she says, and continues on antidepressants. As a result of the trial, she also reordered her life, committing more time to things that are emotionally sustaining and letting go of those there weren’t.

“I think that trial was the single most effective thing I’ve done to manage my mental health, and I tried almost everything,” she says. “It leads me to believe that we need to radically change how we think about mental health.”

 
Last edited:
dt_170126_iv_drip_800x600.jpg



Ketamine infusion therapy: A promising way to treat mental illness

by Rachel Ausman | News 8000 | Oct 08 2019

1 in every 6 adults will have depression at some point in their life, affecting nearly 16 million Americans every year. That's according to the CDC. But a new business in Winona is offering alternative ways to beat these statistics.

Ketamine infusion is available at Bloom Neurotherapy in Winona. A business that feeds ketamine through an IV, helping people with medication-resistant depression, PTSD, anxiety and suicidality.

Ketamine has been used for decades as a clinical anesthetic, and was even used in the Vietnam War -although people most often understand ketamine as a party drug called "Special K".

As research continues to unfold about ketamine and it's effect on the brain and body, professionals are finding significant benefits with ketamine and mental health. Giving patients immediate and effective results.

Co-owner of Bloom Neurotherapy, CRNA, and Anesthetist for 18 years, Beth Maki says, "Current research shows that if you can give those first six infusions within 14 days, 71% of people will enter remission from their mental health issues."

It typically takes 6-weeks for an anti-depressant prescription to feel these effects.

In addition to the physical effects of ketamine, Maki describes the infusion treatment as giving patients a light, floaty feeling.

"It kind of takes you out of your body. Ketamine is considered a dissociative anesthetic, which means that it dissociates you from your normal, everyday reality. It kind of helps you shed the ego. It gives you a chance to look at your life from a new perspective and maybe come up with new solutions to your old problems that you've always had," says Maki.

Once a client enters into remission, they are set up with a 'Mood Monitor' app on their phones. The app asks the patient a question every day, plotting the answers on a graph, logging the effectiveness of treatment.

Bloom Neurotherapy's treatments are currently not covered by insurance. To qualify for the treatment, clients must have a written diagnosis, and they must have tried at least two medications already.

 
Last edited:
800%20Roland_and_Matt.jpg



Are psychedelics the answer to chronic mental health issues?*

by Alberto Kanost | Sep 19 2019

Magic mushrooms, most popularly characterized as a drug that causes users to tune out, are being found to have the ability to help people tune in to their own psyches and overcome barriers.

After years of re-establishing the groundwork in the research of psychedelics, Johns Hopkins University School of Medicine opened The Center for Psychedelic & Consciousness Research to test the effectiveness of magic mushrooms and other psychedelic drugs to treat mental illness and addiction.

According to the author and journalist, Micheal Pollan psychedelics were made illegal in the 1970s after a frenzy of bad media coverage, tying them to counter-culture and the hippie movement.

It took more than 30 years before research into their possible medicinal applications caused them to began to emerge again.

Pharmacological research happens in four phases, the first phase being the “safety study,” where the drug is exposed to volunteers and its risks are evaluated. A safety study for psilocybin, the active ingredient in mushrooms, was conducted at UW-Madison, where they determined that psilocybin was safe enough to advance into later phases of research.

Dr. Toby Campbell, an end-of-life cancer doctor at the UW School of Medicine and Public Health, works with people who are anxious and depressed about dying, as well as have significant fatal illnesses. He was one of the doctors who oversaw the more recent psilocybin study. Campbell believes that these drugs could seriously help aide those at the end of their lives remedy their fear of death.

“Its all just a bunch of nerd stuff at this point,” Campbell said. “But psilocybin really seems to help people.”

Campbell went on to say that "since the drug isn't FDA-approved yet, this research could get shut down in an instant — advising that for numerous reasons, the research needs to be extremely careful and thoughtful."

The room in the UW School of Pharmacy where the psilocybin study was conducted in is modeled after the room where they dose patients at the CPCR at Johns Hopkins University. This speaks to what Campbell described as “coordination with Johns Hopkins.”

Roland Griffiths, director of the CPCR, neuroscientist and professor of behavioral biology has been conducting research on mood-altering drugs for 40 years.

After serious endeavors in meditating, he became extremely interested in the “nature of spiritualism.” This led him to reacquaint himself with research that had gone on in the 1950s and ‘60s that showed how hallucinogens like psilocybin could give “mystical experiences” much like those reported from intense and methodical meditation sessions.

Before the center opened, Griffiths and some of his colleagues sought and ultimately gained approval to administer psilocybin to people who never experienced the drug. This is what began the Johns Hopkins Psilocybin Research Project involving 245 participants in over 600 sessions.

The sessions were held in a living room-like environment where participants took a capsule containing psilocybin, laid on a couch, were encouraged to use an eye mask and to “look inward.” If fear or anxiety arrives, trained human monitors were there to direct and provide assurances.

Most volunteers reported experiencing “a feeling of unity, that people and all things are connected, a sense of sacredness, joy, love and a deep sense of encountering an ultimate reality,” Griffiths said in a TED Talk from 2016.

Continued research of the Johns Hopkins Psilocybin Project studied psychologically-distressed cancer patients, who Campbell is the most interested in with regard to administering psilocybin.

The study conducted on cancer patients consisted of administering two groups of patients — one group receiving a low dose, and the other a high dose.

Results collected five weeks after the “trip” showed that 32 percent of patients who were given the low dose experienced clinically significant improvement from a depressed mood, compared to 92 percent of patients who were given a high dose. The researchers again surveyed the high dose patients six months after their “trip,” finding that 80 percent had sustained their clinically significant improvement in mood.

Griffiths outlined the meaning of this in his TED Talk, saying that not only do high doses of these drugs have implications with improving the mood of patients grappling with the imminent idea of their death, but also that the effects are long-lasting. These results are similar to that of studies on anxiety using the same drugs.

“I think that the trial was the single most effective thing I’ve done to manage my mental health, and I had tried almost everything,” said Rachel Peterson, a participant in a recent psilocybin trial at Johns Hopkins University.

According to Griffiths, these effects are unprecedented in the field of psychiatry. He went on to mention that psilocybin also has greater efficacy in helping cigarette smokers quit than any available options for those seeking to quit.

“Research is showing that under supported conditions psilocybin can occasion mystical-type experiences associated with enduring positive changes in attitudes, mood, and behavior,” Griffiths said concluding his presentation at TEDMED, the annual conference focusing on health and medicine.

Now after $17 million dollars in private funding, The Center for Psychedelic and Consciousness research has opened, giving a foothold to this revived science.

“My initial impression is that these compounds can be helpful, and there is no problem in studying and researching psilocybin,” Campbell said. “I am extremely supportive...and on-board with the work going on at Johns Hopkins.”

*From the article here :
 
Last edited:
photo-1535037532858-83180dabddb0



How psilocybin treats mental health disorders naturally*

by Încrosnatu Dănuț | Sociedelic | Sep 1 2019

Psilocybin has been decriminalized this year, 39 years after it was banned in 1970.

Various treatments are available to combat depression, schizophrenia, anxiety, and PTSD. This change has drawn attention to psychedelic therapies being a promise to fight mental illnesses in the USA and Australia.

The number of people diagnosed with mental health problems has dramatically increased in the past five years. Depression and anxiety have become very common in adults. In the next 10 years, demand for psychiatrists is going to triple.

If we go by evidence, controlled portions of psychedelic therapy under trained professionals could help people with mental disorders without any side effects. In fact, with psychedelic treatments, one can even prevent a relapse of psychological problems.

Researchers are now trying to find more pieces of evidence and update what we know about psilocybin for depression. Before being classified Schedule I, psilocybin was widely researched in the 1960s and used in specific mental disorder treatments.

What psychedelic drugs do

Let us tell you what psychedelic drugs are within the context of modern science.

Psychedelic psychotherapy is a type of mental illness treatment where a small quantity of psychedelic drugs is used in a highly regulated clinical setting. Some of the essential psychedelic drugs include psilocybin, MDMA (ecstasy drugs), and LSD. These are not illegal, sold behind the scenes drugs. They are, in fact, pharmaceutical graded and have to be taken as per the prescribed dosage.

Magic mushrooms are used as a natural treatment for depression by some indigenous communities for over 1000 years. MDMA and LSD, however, were synthesized in different pharmaceutical labs in the early 20th century.

In the 1950s, magic mushrooms and other psychedelic drugs were tagged as the ‘wonder drugs’ for treating a variety of mental disorders, including end-of-life anxiety, alcohol dependence, depression, post-traumatic stress disorder (PTSD).

However, in the 1960s, the drug escaped the clinical sphere and landed among the teenagers. After this incident, followed by a lot of political issues, the drug was banned in 1971.

In the medical field once again

The recent shift in politics and people’s attitude has helped psychedelic drugs to once again gain access to the medical realm. While medical research started yet another time to find Magic Mushrooms’ effectiveness in treating depression.

Meanwhile, the John Hopkins School of Medicine researches showed a positive change in people’s personalities. Such as openness and sociability after they were injected a controlled amount of the drug.

The effects of the drugs were harnessed to reduce depression and anxiety in people with terminal diseases.

After this research, in the following six years, many other significant studies were made on the drug. Few trials disclosed its significance in improving quality of life, while another breakthrough study showed that psilocybin-based psychotherapy effectively treated depression.

Researchers have not stopped with this. Phase 3 trials are in the planning stage. If the drugs are found to be effective in these trails, MDMA and psilocybin will soon become a legal drug, within the next five years.

Certain studies also reveal that psilocybin can be used in treating alcohol and nicotine-addicted patients.

How psychedelic mushrooms work

Magic Mushrooms and other psychedelic drugs produce a mystical state in the minds of people suffering from anxiety and chronic depression, thereby improving their quality of life.

Psilocybin controls the actions of the neural circuit in your brain, which is commonly referred to as the Default Mode Network (DMN).

The DMN defines our resting state, which often becomes distorted when depression and other mental illnesses gain precedence. Psychedelics decrease the activities of DMN temporarily to establish different neural pathways.

Establishing other neural connections reduce our persistent thoughts often characterized by depression. It promotes the creation of new ideas and perspectives about individuals’ personal lives and relationships. It is also found that psychedelic drugs can aid in the reformation of neuronal connections that have faded in people with long-term depression.

However, researchers are yet to understand the mechanism of this process.

That being said, it is simultaneously observed that psychedelics can worsen certain medical conditions. These conditions include personality disorders and other behavioral conditions such as schizophrenia and heart and liver ailments.

The latest trial on psilocybin-assisted therapy for depression is likely to complete in 2021.

If the results of all clinical studies in phase 3 confirm the promise made in the completed trials about magic mushrooms, the chances of psychedelic drugs becoming approved for medical treatments in the next 3 years is excellent.

For proving the efficacy of the drug, we have to continuously demonstrate its safety and declare it as a viable and natural approach to treat depression.

*From the article here :
 
Last edited:
psychedelic-psilocybin-peyote-ayahuasca.jpg



Psychedelics found to improve the symptoms of psychiatric disorders

By Kimberly Lawson

Psychedelics with and without accompanying psychotherapy have been found to reduce symptoms associated with at least eight different psychiatric diagnoses, a new scientific review reports.

“The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders,” the paper states. “The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated.”

While the authors noted that “it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design,” the concluded that “this body of pilot literature suggests the possibility of therapeutic benefit that could outweigh adverse events and warrants more rigorous, definitive investigation.”

The findings were published in the Journal of Psychiatric Practice earlier this month.

Last year, an estimated 5.6 million Americans reported using psychedelics, which are illegal, though federal agencies have acknowledged their potential medical value. To better understand how these psychedelic substances may help people, researchers at the University of Texas Health Science Center at San Antonio reviewed clinical studies that involved ayahuasca, ibogaine, ketamine, LSD, MDMA and psilocybin.

The review’s authors focused on 16 studies published between 1946 and 2017. Here’s a look at some of their findings:

- In two related studies, patients who were diagnosed with recurrent major depressive disorder saw their symptoms reduced with a single dose of ayahuasca. Though the psychedelic substance was generally well-tolerated, half of study participants experienced vomiting.

- Patients with alcohol use disorder who were given a high dose of dipropyltryptamine while attending therapy for multiple weeks “demonstrated significant improvement on multiple rating scales, including depression, self-regard, and insight during post-testing, the review states."

- In a study of 75 participants with alcohol, cannabis and cocaine use disorders, 61 percent reported abstaining from their substance of choice for an average of five months after being treated with ibogaine and behavioral therapy.

- Researchers found that ketamine-assisted psychotherapy helped more people abstain from alcohol abuse than those who underwent the same three-month psychotherapy course without the psychedelic. “The authors,” the review states, “reported treating over 1000 patients with ketamine psychotherapy without any reports of prolonged psychosis, flashbacks, agitation, or ketamine abuse.”

- Patients diagnosed with alcohol use disorder may find it easier to abstain from drinking with a single dose of LSD than daily use of other common medications used to treat the disorder, according to a meta-analysis reviewing six randomized controlled trials.

- A small study found that higher MDMA dosage with therapy appeared to impact chronic PTSD symptoms related to sexual trauma more than lower doses of the substance.

- Another small study found that patients with varying cancers and related anxiety saw their anxiety and depressive symptoms reduced after a moderate dose of psilocybin, though the effects were not “statistically significant” until six months after administration. Researchers also found that patients experienced a short-lived increase in heart rate and blood pressure after taking psilocybin.

“In 15 of the 16 studies, it was reported that psychedelic monotherapy or augmentation therapy produced clinically significant reduction in symptomatology,” the review states. “Many of these improvements occurred in subjects who had previously failed to respond to traditional treatments. Furthermore, many studies demonstrated improvement in less time than commonly observed with traditional psychopharmacology or therapy.”

Additionally, the review‘s authors found that all but one of the eight studies that examined how psychedelics may affect substance use disorders reported “significant benefits.”

“While the successes reported in the studies reviewed here are intriguing, they should not be misinterpreted as an endorsement for the use of psychedelics to medicate any of the above conditions,” the authors wrote. “This review was inherently biased by the selection criteria, and dangers of psychedelic drug use were not the focus of this review. This should not, however, distract from the potential benefits described.”

The review concluded by pointing out structural barriers to expanded research on psychedelics.

“Despite promising findings in therapeutic psychedelic trials, current factors, including funding, laws, and stigma, continue to impose limitations on further research,” they wrote. “Schedule 1 classification makes study development difficult, costly, and prolonged. Funding by both government and pharmaceutical companies is nonexistent.”

Psychedelics help patients with depression and anxiety

Amidst the growing global movement to decriminalize certain psychedelic drugs, a new scientific review found that ayahuasca, psilocybin and LSD may help with two of the most common psychiatric disorders in the world.

“In all studies,” the paper’s authors write, “psychedelic administration caused statistically significant reductions in depression and anxiety symptoms. These findings corroborate the limited previous research conducted in animal studies and healthy volunteers, as well as anecdotal evidence describing improved mood and reduced feelings of apprehension following psychedelic administration.”

“In a supportive setting, ayahuasca, psilocybin, and LSD consistently produced immediate and significant anti-depressant and anxiolytic effects that were endured for several months.”


Researchers in London analyzed seven prior studies with a total of 130 patients who had been diagnosed with depression and/or anxiety. One looked at the effects of ayahuasca for major depressive disorder, one measured how LSD helped with anxiety linked with a potentially deadly disease and five used psilocybin as an intervention for treatment-resistant depression, anxiety and depression associated with life-threatening and advanced-stage cancers.

Here’s what the review’s authors found:

- In a small study of six patients, a single dose of ayahuasca reduced test scores measuring depressive symptoms by up to 82 percent at one, seven and 21 days after intake.

- Patients who participated in a study investigating the efficacy of psilocybin for treatment-resistant depression saw their symptoms “significantly improved from baseline to 1 week and 3 months post-treatment, with maximum effect at 2 weeks.” A follow-up study at six months found “the anti-depressant and anxiolytic effects of psilocybin were sustained and remained significant at 6 months post-treatment.”

- Three more double-blind, placebo-controlled cross-over trials involving psilocybin had similar positive results in reduction of symptoms associated with anxiety and depression linked to life-threatening cancer.

- In another study, 12 patients with anxiety associated with the fear that they might die because of a disease were treated with drug-free psychotherapy sessions and two psychotherapy sessions that involved either an experimental dose of LSD (200 micrograms) or a smaller, placebo dose of LSD (20 micrograms). At their two-month follow-up assessment, patients who received the experimental dose reported their symptoms were “significantly reduced,” and these results were still evident at 12 months.

In short: Psychedelics appeared to help patients manage their anxiety and depression better.

“These improvements were consistently observed across a variety of rating scales, and this is suggestive of a genuine therapeutic effect rather than a specific scale’s tendency to show a positive effect,” the study states. “Moreover, the lack of equivalent symptom reduction in control patients indicates that the anti-depressant and anxiolytic effects can be attributed to psychedelic intervention.”

The authors also found that many patients “described the experience as spiritually meaningful, resulting in decreased disease-related demoralisation and hopelessness as well as improved quality of life.”

Importantly, researchers found that the psychedelic treatment “was well-tolerated with no persisting adverse effects.” The most common short-term side effects they reported included transient anxiety, headaches, nausea, in addition to mild increases in heart rate and blood pressure.

“Given the limited success rates of current treatments for anxiety and mood disorders, and considering the high morbidity associated with these conditions,” the study’s authors conclude, “there is potential for psychedelics to provide symptom relief in patients inadequately managed by conventional methods. The novelty of this research means that before psychedelics’ wider-use can be contemplated, the results presented herein need to be replicated in larger studies with a longer followup to determine lasting efficacy and safety.”

The review, published online in the Journal of Affective Disorders last week, comes just two months after the Food and Drug Administration and the National Institutes of Health sent a letter to a senator that acknowledges the potential healing properties of certain psychedelic substances. The federal agencies noted, however, that they have no plans to reclassify any psychedelics currently in the restrictive category of Schedule I, such as psilocybin, LSD and MDMA.

 
Last edited:
46823933565_78ee444201_b.jpg



Risks of cannabis use for mental health treatment outweigh benefits

by Sarah Boseley | The Guardian | 28 Oct 2019

New study shows evidence of positive outcomes is scarce while symptoms can be exacerbated.

The use of cannabis medicines to treat people with depression, anxiety, psychosis or other mental health issues cannot be justified because there is little evidence that they work or are safe, according to a major new study.

A review of evidence from trials conducted over nearly 40 years, published in the journal Lancet Psychiatry, concludes that the risks outweigh the benefits. "And yet," say the authors, "they are being given to people with mental health problems in Australia, the US and Canada, and demand is likely to grow."

Prof Louisa Degenhardt of the National Drug and Alcohol Research Centre at UNSW Sydney, Australia, lead author of the study, said "the findings have important implications in countries where medical is allowed."

“There is a notable absence of high-quality evidence to properly assess the effectiveness and safety of medicinal cannabinoids compared with placebo, and until evidence from randomised controlled trials is available, clinical guidelines cannot be drawn up around their use in mental health disorders,”
she said.

“In countries where medicinal cannabinoids are already legal, doctors and patients must be aware of the limitations of existing evidence and the risks of cannabinoids. These must be weighed when considering use to treat symptoms of common mental health disorders. Those who decide to proceed should be carefully monitored for positive and negative mental health effects of using medicinal cannabinoids.”

The authors looked for evidence of an effect of medicinal cannabinoids in trials conducted in depression, anxiety, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder (PTSD) and psychosis. They found 83 studies in 3,000 people. But the evidence of a positive effect was sparse.

There was, they said, “low-quality evidence” that THC, one of the derivatives of cannabis, could be helpful to people with multiple sclerosis or chronic pain who were also suffering from anxiety. But it made people with psychosis worse.

While there is little evidence that cannabinoids can help, the authors found more evidence in “a large body of research” of the potential harms. “This research suggests that cannabis use can increase the occurrence of depression, anxiety, and psychotic symptom,” says the paper.

A well-constructed study found that smoked cannabis actually increased the risk of acute psychotic symptoms. And young adults, the age group more likely to suffer from anxiety, depression and psychosis, are more likely to become dependent if they use cannabis daily over a long period of time.

“These risks, and the limitations of existing evidence, need to be weighed when considering the use of medicinal cannabinoids to treat symptoms of common mental disorders. Those who decide to proceed should be carefully monitored for positive and negative mental health effects of using medicinal cannabinoids,” they write.

In a comment piece in the journal, Deepak Cyril D’Souza of Yale University School of Medicine in New Haven, Connecticut, said that “in light of the paucity of evidence, the absence of good quality evidence for efficacy, and the known risk of cannabinoids, their use as treatments for psychiatric disorders cannot be justified at present.”

In modern medicine, it is normal practice to prove safety and efficacy in trials before drugs are allowed to be given out to patients.

“If cannabinoids are to be used in the treatment of psychiatric disorders, they should first be tested in randomised controlled trials and subjected to the same regulatory approval process as other prescription medications,” he add.

 
Last edited:
AdobeStock_186924258.jpeg



Are magic mushrooms beneficial for mental health therapy?

WorldHealth.Net | Oct 28 2019

Magic mushrooms are fungi that contain the active compound psilocybin, a psychedelic that affects cognition, perception, and mood; psilocybin is being investigated for its effects on mental health, and the potential to address various mental health conditions.

These are wild mushrooms that can be found in different parts of the world, most of which belong to the genus Psilocybe; P. cubensis is the most common source of psilocybin with the principal active compounds also including another psychedelic compound called psilocin.

This mushrooms can be taken in a variety of ways such as made into a tea or eaten fresh. Some 200 different species have been identified, each containing various quantities of psilocybin which is currently being studied as a potential treatment for depression and has been given a breakthrough therapy designation by the US FDA; that being said, it still remains listed as a Schedule 1 controlled substance.

Psilocybin is suggested to exert its effects by activating serotonin receptors which are located in the prefrontal cortex responsible for a range of complex behaviors and personality development. Although it is classed as a hallucinogen psilocybin does not always cause it. Sometimes it does distort perception of things in a person’s environment, and the effects can be influenced by expectations, past experiences, and dosage.

Matthew Johnson, associate professor at Johns Hopkins University, has been studying psilocybin for years recently said in an interview with Healthline that the active compound in magic mushrooms may be of benefit to people with various health conditions. He says that many people mistakenly believe that psilocybin is an addictive drug, but it is not, as it doesn’t induce the same euphoria and dopamine response as do drugs of addiction.

According to Johnson, psilocybin has a higher success rate than nicotine replacement when it comes to helping people quit smoking, and one year after quitting 67% of the people in the study were biologically confirmed to still be smoke free, and it is substantially better than the best medications prescribed to help people quit smoking.

Before psilocybin was banned thousands of patients benefited from its use, the only cases with long lasting psychiatric harm were those of schizophrenics, or those who thought they had a predisposition for that mental illness. Johnson is optimistic about his results comparing cognitive behavioral therapy with psilocybin treatment, and hopes that it will one day be approved for treatment of a variety of medical conditions. Magic mushrooms are believed by Johnson to have the potential to transform psychiatry, and the likely application as a treatment for depression as well as addiction points to the possibility of different disorders sharing more similarities than were previously thought.

Despite his optimism Johnson emphasizes the risks of using psilocybin, and discourages its use outside of a legal and approved medical framework as it can still be abused and used in ways that can harm users or other people.

 
Last edited:
18122882234_ed63367a60_b.jpg

Kings College London

How CBD takes effect in the brains of people with psychosis

Kings College London | Neuroscience News | 29 Jan 2020

Researchers from King's College London have shown that CBD alters the brain activity in people with psychosis during memory tasks, more similar to the activation seen in people without psychosis during the same tasks.

Published in Psychological Medicine, the researchers used fMRI scans to examine the brain activity of 13 people with a diagnosis of psychosis under the influence of a single dose of CBD or placebo and 16 controls whilst they were undertaking a memory task. The researchers showed that, during the task, there was a different pattern of activity in the prefrontal and medio-temporal brain areas of people with psychosis under placebo compared to the activity seen in those without psychosis. When those with psychosis were given one dose of CBD, the activation in these brain areas became more like the activation seen in control subjects.

Senior author on the study, Professor Sagnik Bhattacharyya, from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London said: “Our study provides important insight into which areas of the brain CBD targets. It is the first time research has scanned the brains of people with a diagnosis of psychosis who have taken CBD and, although the sample is small, the results are compelling in that they demonstrate that CBD influences those very areas of the brain that have been shown to have unusual activity in people with psychosis.”

CBD is one of over 100 chemical compounds known as cannabinoids that are found in the cannabis plant. There has been recent interest in the use of cannabidiol (CBD) as an alternative to current antipsychotic medicines as it could prove to be more tolerable generally and more effective for a subset of people who do not respond to available antipsychotics. Its use has been associated with a decrease in symptoms of psychosis and changes in brain activity during verbal memory tasks in patients at high risk of psychosis.

The study also showed that activity in the striatum and the activity in hippocampus was more co-ordinated in people with psychosis, indicating there was a greater functional connectivity between these two areas in this group compared to controls. After one dose of CBD this functional connectivity was reduced in people with psychosis and became more similar to that seen in the controls. Those people with psychosis continued on their existing antipsychotic treatment throughout the study.

The results indicate that CBD has a moderating effect on the altered pattern of brain activity in the prefrontal, mediotemporal and striatal areas in people with psychosis. The study also showed that psychotic symptoms did show a decreasing trend after the dose of CBD but researchers highlighted that no definitive conclusions could be drawn about this effect as the study did not look at sustained use of CBD and the sample size was small.

Professor Bhattacharyya added: “This study provides important insight into the brain mechanisms behind the antipsychotic effects of CBD. It gives confidence in the antipsychotic potential of CBD by demonstrating that it targets the function of brain regions implicated in psychosis and indicating that even a single dose may ameliorate some of the brain function alterations that may underlie psychosis. The finding that psychotic symptoms may show a trend towards improvement in this group even after one dose of CBD is encouraging, but requires a larger scale clinical trial to investigate if the effects would continue with longer term treatment. The results form an important part of the picture that scientific research is building on the effects of CBD and will help support the case for further clinical trials on the use of CBD in different stages of psychosis as well other neuropsychiatric diseases such as Parkinson’s disease where a proportion of patients may also experience psychotic symptoms."

 
Last edited:
1-teens.jpg



Bullied teens struggle with long-term mental health issues

by Jared Wadley | University of Michigan | 24 Mar 2020

Bullying can make life miserable in the short term for teens, but its impact can also linger into young adulthood, says a University of Michigan researcher.

Much is known about the negative effects of bullying, ranging from depression to poor performance in school, but a new study indicates that bullied teens can suffer long-term mental health problems that last into early adulthood.

How these individuals perceive themselves contributes to these outcomes, said study author Janette Norrington, U-M doctoral student in sociology. The study, which appears in the journal Youth & Society, also indicates that verbal abuse and peer harassment are more harmful than physical victimization or social exclusion.

Previous research has shown that youths suffer short-term mental health consequences, but less is known about the negative, long-term impact between the ages 18 to 24.

Norrington used longitudinal data from the Panel Study of Income Dynamics to examine teen self concept as a mediator in the relationship between adolescent peer victimization and psychological distress in emerging adulthood.

Self-concept, which is the image people have of themselves or self worth, is a link between teen bully victimization and later mental health. Bullying includes physically harming, making fun of, excluding, and spreading rumors about a person.

"Bully victimization damages how people view themselves in adolescence and that negative view can linger into adulthood, contributing to poor mental health," she said.

Norrington examined the responses of more than 1,400 adolescents in 2002 and 2007, who were questioned about the frequency that classmates hit them and picked on them, had their things (money and lunch) taken and were left out of friends' activities. In 2009 and 2013, as adults, they were asked how often in the past month they felt nervous, hopeless, sad and worthless.

Peer victimization is still associated with higher levels of psychological distress, but the impact is lessened among those with high self-esteem, the study found.

"Intervention and mental health programs should focus on enhancing the self-concept of adolescent bully victims," Norrington said. "One way to do this would be to emphasize peer support to help youth feel valued and develop self-confidence."

"In addition, adult mental health programs can also address former bully victims' self-concept and help them process their past peer victimizations to improve their mental health,"
she said.

 
Last edited:
08xp-columbia1-videoSixteenByNineJumbo1600.jpg

Columbia University

Experimental schizophrenia drug could reduce long-neglected symptoms

by Kelly Servick | Science Magazine | 15 April 2020

For the first time in decades, researchers may have a new way to tweak brain signals to treat psychosis and other symptoms of schizophrenia. Results from a 245-person clinical trial hint that a compound called SEP-363856, which seems to act on neural receptors involved in dopamine signaling, might address a broader range of schizophrenia symptoms than currently available drugs do—and with fewer side effects.

“If these results are confirmed, this will be big, big news,” says Jeffrey Lieberman, a psychiatrist at Columbia University. The drug’s developer, Sunovion Pharmaceuticals Inc., identified it through an unusual screening process not guided by the brain circuits and receptors already implicated in the disease, Lieberman says. “It was a big gamble on their part. This study suggests that it may pay off.”

The biological basis of schizophrenia remains a puzzle, but researchers have linked patients’ hallucinations and delusions to an excess of the chemical messenger dopamine. To inhibit dopamine signaling, existing antipsychotic drugs bind to a type of dopamine receptor on neurons called D2. These drugs help control abnormal perceptions and thoughts—the “positive” symptoms of schizophrenia. But they don’t do much to address either cognitive impairments or the “negative” symptoms, including lack of motivation, dulled emotion, and social withdrawal. “Those negative symptoms are often the most devastating,” says Diana Perkins, a psychiatrist at the University of North Carolina, Chapel Hill. “A person can become, at the most extreme, robotlike.”

"The first generation of antipsychotic drugs that emerged in the 1950s sometimes actually worsened these negative symptoms,"
Perkins says. "And tamping down on dopamine signaling can lead to side effects including tremors and other involuntary movements. A second generation of D2-targeting drugs has reduced the risk of some of these side effects, but many cause weight gain and other metabolic problems."

Sunovion started its drug search wanting to avoid D2 receptors. “It was a bit of an antitarget approach,” says Kenneth Koblan, the company’s chief scientific officer. “If a compound worked through the D2 system, we didn’t want to work on it.” The researchers relied on a drug screening method, developed by PsychoGenics Inc., that used artificial intelligence to analyze the behavior of mice exposed to hundreds of candidate compounds. The researchers looked for a compound that mimicked the effects of D2-targeting drugs. One stage of the testing involved trying to reverse the effects phencyclidine, better known as PCP, which causes hyperactivity and other schizophrenialike behaviors.

SEP-363856 rose to the top of the heap. This compound didn’t touch D2 receptors, the researchers found, but it activated two other types of neural receptors—known as TAAR1 and 5-HT1A—that help regulate the synthesis and release of dopamine. The mechanisms of the drug aren’t fully clear, but the researchers suspect they’ve hit on a new way to tweak dopamine signaling.

The clinical trial tested SEP-363856’s effects in people who were still early in the course of schizophrenia—none had been hospitalized for acute psychotic symptoms more than twice. During a flare-up of these symptoms, the participants, who ranged from 18 to 40 years old, spent 4 weeks in the hospital taking either SEP-363856 or an identical-looking placebo pill once a day. Clinicians then evaluated a broad set of schizophrenia symptoms using a measure called the Positive and Negative Syndrome Scale (PANSS), which gives scores ranging from 30 to 210, with a higher score representing worse symptoms. On average, participants scored roughly 100 on entering the study; after 4 weeks, the average score in the drug group had dropped by 17.2 points, versus 9.7 in the placebo group, the researchers report today in The New England Journal of Medicine.

“This is great news,” says Romina Mizrahi, a psychiatrist at the University of Toronto. The trial didn’t directly compare SEP-363856 to other drugs, but she notes that the reduction in PANSS scores is similar to results from some trials of now-approved antipsychotic drugs.

The group taking SEP-363856 also had a larger drop than the placebo group on another scale, one meant to measure negative symptoms like lack of pleasure and motivation. Though the study wasn’t statistically designed to draw conclusions using this secondary measure, this early indication “is a big deal, and it’s potentially a game changer,” Perkins says. “If it’s confirmed … that would mean a lot for many patients and their families.”

Rates of side effects, including movement disorders, nausea, agitation, and drowsiness, were low in both groups. And although SEP-363856’s long-term effects on metabolism aren’t clear, the compound didn’t cause major weight gain in either the 4-week trial or a 26-week extension that included 156 of the participants, all of whom got the experimental drug.

Sunovion isn’t the only company looking to sidestep D2 receptors in treating schizophrenia. Karuna Therapeutics is studying xanomeline, a compound with a different neural target, which Eli Lilly developed in the 1990s and later abandoned after finding that many patients experienced side effects that include nausea and dizziness. (Karuna aims to reduce those effects by combining xanomeline with another drug.) The company announced positive results from a study involving 182 patients last year.

In September 2019, Sunovion launched a larger, phase III trial that will include more than 1000 people, designed to prove the drug’s efficacy and win regulatory approval. Koblan says he can’t estimate when the trial might yield results, citing COVID-19. “I would be very comfortable answering that question if we weren’t in the midst of a pandemic,” he says.

 
Last edited:
portrait-of-psychopharmacologist-dr-alexander-sasha-shulgin-developer-picture-id139299307



Psychedelic drugs saved my life

by Khaliya | 7 Aug 2017

Mental-health advocate Khaliya points to evidence that shows psychedelic drugs like psilocybin could transform the way we treat mental health. The world is in the throes of a mental-health crisis, as depression and dementia afflict spiraling numbers of people.

In March 2017, the World Health Organization declared that depression is the leading cause of ill health and disability worldwide. Over 300 million people are living with it, an increase of more than 18 per cent between 2005 and 2015. But help is at hand - if we can reach out and grasp it.

A group of drugs long considered taboo is poised to transform the way we treat mental health. Recent research suggests that psychedelics could probe to be powerful tools not only to treat, but also potentially cure, many mental health problems regarded as chronic.

Psychedelics do something that our current psychiatric drugs cannot: they transform hardwired neural patterns to reroute the very architecture of the brain, sometimes in a single dose. Roland Griffiths, a professor of Psychiatry and Neurosciences at Johns Hopkins University in Maryland, has likened psychedelics ability to bring about neural rerouting as akin to a surgical intervention.

Take psilocybin, better known as magic mushrooms. "A single dose of the drug can do in 30 seconds what it takes antidepressants three to four weeks to do," according to David Nutt, professor of neuropsychopharmacology at Imperial College London.

A study published in the Journal of Psycho-pharmacology on people with anxiety associated with life-threatening illness suggested that LSD-assisted psychotherapy was successful in almost 70% of subjects, with positive effects lasting more than a year and causing no lasting adverse reactions.

Given the overwhelmingly positive results of these and other trials, one would think the clinical use of psychedelics would represent a sea change in our approach to mental-health treatment. But, sadly, outdated societal prejudice against psychedelics is proving a formidable handicap, hampering research and keeping many in need from reaping the benefits.

Strict anti-drug legislation that still criminalizes the use of such substances has pushed psychedelic-assisted treatments underground: unless you are among the lucky few accepted into a clinical trial, your only options are to find an unlicensed practitioner, attempt to do it yourself illegally or travel to places where the compounds are legal.

Growing numbers of people are doing just that, and in recent months, there has been flurry of articles on the topic which have stoked curiosity about the potential of psychedelics. In April of this year, the Psychedelic Science Conference in California was attended by more than 3,000 people who traveled from across the globe to learn about recent advances.

Although it is heartening that more people are finding relief, ad hoc experimentation is not the way to go. We must bring this research into the mainstream, guarantee adequate funding and shield well-intentioned facilitators from criminal prosecution.

I should know. I was once the victim of a violent robbery, which left me shattered. Out of desperation I turned to psychedelic-assisted psychotherapy. It helped save my life.

Mental-health practices around the world are in desperate need of an overhaul, and psychedelics could be just the hack we need to achieve such fundamental - and indispensable - change. I believe mental health to be a human right, and as such it is nothing short of our duty to follow, and fund, the science.

http://www.wired.co.uk/article/magic...chedelic-drugs
 
Last edited:
surreal-402830_640_0f1a2a69a972695df7b220e65d3770cf.jpg



Physician psychotherapy unavailable to 97% of people with an urgent mental health need

by The Centre for Addiction and Mental Health | Medical Xpress | 11 Mar 2020

Publicly-funded physician psychotherapy is only available to a tiny fraction of those with urgent mental health needs in Ontario, according to a study by the Centre for Addiction and Mental Health (CAMH) and ICES published in CMAJ Open.

The study confirms that there are far too few physicians providing publicly-funded psychotherapy in Ontario to meet the demand for it, and those physicians are concentrated in large urban areas and are rarely able to take on new patients with urgent mental health needs.

"The need for innovations in mental health to improve access and quality of care is urgent," said lead author Dr. Paul Kurdyak, Director of Health Outcomes and Performance Evaluation in the Institute for Mental Health Policy Research at CAMH and lead of the Mental Health and Addictions Research Program at ICES. "But increasing the number of physicians who provide psychotherapy alone will not solve the existing problem of poor access to psychotherapy in a publicly-funded system."

The study focused on the availability of publicly-funded psychotherapy provided by physicians in Ontario. Psychotherapy is an evidence-based treatment for conditions like depression and anxiety, two of the most common psychiatric disorders. Treatment guidelines suggest that structured, evidence-based therapies like Cognitive Behavioural Therapy (CBT) should be a front-line treatment option for patients with mild to moderate depression or anxiety.

Historically, most access to publicly-funded psychotherapy in Ontario has been provided by psychiatrists or family physician psychotherapists. But there are less than 1,000 of them in Ontario (out of a total physician population of over 12,000) and they see a much smaller number of patients on average.

While access to urgent care was low in general (more than half of all patients who sought care for mental health including addictions issues at an Emergency Department did not see any physicians within a month of the visit) access to psychotherapist physicians was even lower. Only two to three per cent of patients with urgent need were able to access psychotherapist physicians.

One part of the solution according to the study is to allow psychotherapists and other clinicians who are not physicians to provide publicly-funded CBT. It points to a program initiated in England that involved training non-physicians to provide publicly-funded CBT as one model for Ontario to consider.

CAMH has been one of four mental health hospitals in Ontario taking part in a three-year pilot project based on the England model, and last week the Ontario government announced it was expanding that program under the name Mindability to provide publicly-funded CBT to an additional 80,000 patients a year. But the study estimates that more than ten times that amount of patients—up to 900,000 a year in Ontario—could benefit from psychotherapy.

"Evidence-based psychotherapy should be available to all patients suffering from the most prevalent mental disorders," said Dr. Kurdyak. "Our study suggests that there are far too few publicly-funded physician psychotherapists to meet the needs of these patients."

 
Last edited:
mentalhealth.jpg



Rising anxiety and mental health issues are a growing concern as people continue to work from home

by Microsmallcap.com | CISION PR Newswire | 18 Jun 2020

Isolation, lack of social connection and overall uncertainty are already taking a toll on everyone's mental health during the pandemic. While Zoom usage skyrocketed from 10 million users to 300 million users during the first three months of isolation, so have prescriptions for anxiety disorders like Eli Lilly and Company's Prozac, which saw sales rise 9% from 27 million to 29 million between March 2019 to March 2020.

Mental health and communications experts are warning that Zoom creates mental fatigue and anxiety because users feel pressured to "really be on and be responsive at all times." The nature of speaking over video calls also requires more mental energy and focus, which can create additional stress.

This "new norm" of interacting is only worsening an already-serious problem in the United States. Anxiety disorders are the most common mental illness in the US, affecting 40 million adults, or 18% of the population every year. Now, with pandemic-related stress mounting, antidepressants such as Eli Lilly and Company's Prozac and Pfizer's Zoloft are running in short supply in various regions due to increased demand. Which is why disruptive solutions for anxiety disorders and mental health are becoming increasingly important.

Groundbreaking psychedelic drug company Mind Medicine (MindMed) Inc. is working on disruptive approaches to treat anxiety and other mental health issues. The company's newly launched Project Lucy is the first experiential, psychedelic-assisted therapy to be added to the company's drug development pipeline.

Mind Medicine has also established a project task force to prepare a briefing package for a potential Investigational New Drug (IND) with the Food and Drug Administration (FDA). The task force is working to prepare and analyze data relevant for the discussion with the FDA relating to the potential opening of a US IND for the treatment of anxiety disorders.

Prior to the launch of Project Lucy, MindMed acquired exclusive, worldwide data rights to eight completed or ongoing clinical trials from the University Hospital Basel evaluating LSD based on over 10 years of research. The company plans to assemble and use this data as part of its briefing package to the FDA.

Mind Medicine also received the data and worldwide rights to an ongoing Phase 2 trial for anxiety disorders administered by the world leader in psychedelics pharmacology and clinical research, Dr. Matthias Liechti, and psychedelic therapy expert, Dr. Peter Gasser. This data will help build MindMed's understanding of LSD for anxiety disorders and its platform for LSD as a prescription medication for serious mental health conditions.

Many mental health disorders appear to be interconnected, which presents a unique opportunity for companies like Mind Medicine. to innovate and create a novel treatment paradigm. For example, approximately 50% of ADHD patients also suffer from anxiety disorders and up to 90% of patients with General Anxiety Disorder also have symptoms of another mental health problem, such as depression or substance abuse.

Will working from home become the new norm?

With employees around the world going into their third month of remote work, some companies are contemplating whether or not it should become the new normal. After all, studies have shown that employees are, in fact, a lot more productive while working from home compared to being in the office. In fact, one 2015 study even suggests that working from home can improve performance by 13% in the first nine months away from the office.

That's likely why tech giant Facebook has decided to allow employees to work remotely permanently. In May, the company's CEO Mark Zuckerberg told workers during a live-streamed staff meeting that within a decade up to half of Facebook's over 48,000 employees would work from home. Meanwhile, Google employees are gearing up to work from home for the remainder of the year and are being given a $1,000 allowance to spend on equipment to help outfit their home workspaces.

Although working from home could very well become the new norm, Microsoft Corporation CEO Satya Nadella has warned that making remote work permanent could lead to negative consequences for social interaction and mental health. Even as Microsoft was one of the first companies to shift its tech workforce remotely when the pandemic began to spread across the globe, Nadella believes "switching to entirely remote offices would only replace one dogma with another dogma."

Of course, whether employees return to the office or not, it's evident that the pandemic is taking a toll on many people's mental health. The significant uptick in prescriptions for anti-anxiety medicine in March is a sharp reversal from the pattern over the last five years when the use of benzodiazepines (Xanax, Klonopin, Ativan and Valium) declined by 12%. The reason is that doctors have shifted away from prescribing these meds, which are prone to abuse, in favor of therapy.

It's also encouraging to see companies like Mind Medicine developing potentially non-addictive treatments to combat anxiety and depression for the growing market.

 
Last edited:
Top